New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that biologics were the most common initial treatment prescribed to treat systemic juvenile idiopathic arthritis ...
Nov 1, 2021
0
2
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that higher doses, longer duration of use, chronic kidney disease and Asian race could all be independent risk ...
Nov 1, 2021
0
59
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that hydroxychloroquine, an antimalarial drug and mainstay therapy for lupus, does not appear to be associated ...
Nov 1, 2021
0
1
For patients with psoriatic arthritis, upadacitinib at a dose of 15 mg or 30 mg once daily is more effective than placebo, according to a study published in the April 1 issue of the New England Journal of Medicine.
Apr 1, 2021
0
3
Children with arthritis affecting five or more joints, called polyarticular juvenile idiopathic arthritis (polyarticular JIA), living in less affluent families were twice as likely to report more than an hour of morning joint ...
Nov 9, 2020
0
3
A new study finds that the community in which one lives influences whether they receive postoperative care and rehabilitation after elective hip replacement surgery in a facility or at home. An analysis of a large regional ...
Nov 12, 2019
0
1
Americans living with rheumatic disease face significant healthcare challenges, according to a national patient survey released this week by the American College of Rheumatology and its Simple Tasks public awareness campaign.
Sep 13, 2019
0
5
(HealthDay)—Two position statements developed in relation to drug pricing and step therapy have been issued by the American College of Rheumatology (ACR).
Apr 15, 2019
0
1
(HealthDay)—Funding and division/department support are ranked as critical factors in enabling rheumatologists to develop a career in academic research, according to a study published in the September issue of Arthritis ...
Sep 17, 2015
0
13
The first national investigation of Medicare coverage of biologic disease modifying drugs (DMARDs) found that in starting a single biologic DMARD, patients face more than $2,700 in copayments each year before receiving relief ...
Apr 21, 2015
0
21
